Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01725451 · ClinicalTrials.gov registry record · Phase 1

A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants

A Phase 1 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT01725451: Completed Phase 1 study, sponsored by Eli Lilly and Company.

NCT01725451 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01725451, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

This study will evaluate the effect of deodorant and antiperspirant use and the presence of underarm hair on the absorption of testosterone. Each participant in this study will receive 6 single doses of 30 milligrams (mg) testosterone applied as a solution to each underarm. There is a minimum one day washout period between each dose. This study will last approximately 24 days not including screening. Screening is required within 30 days prior to the start of the study.

Primary Outcome

The AUC from time 0 to 72 hours \[AUC (0-72)\] postdose, based on baseline-corrected concentrations. Baseline-corrected AUC (0-72) was calculated using the measured concentrations of total testosterone minus mean baseline testosterone concentration. Baseline testosterone concentration was the arithmetic mean of 3 predose concentrations.

Interventions

  • DRUG Testosterone
  • OTHER Deodorant Spray
  • OTHER Deodorant and Antiperspirant Combination Spray
  • OTHER Deodorant and Antiperspirant Combination Stick

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2012-11
Est. Completion 2013-01
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT01725451 record still lists

NCT01725451 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 4 interventions - of which Testosterone is the first listed.

NCT01725451 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01725451 about?

NCT01725451 is a clinical study titled "A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants". This study will evaluate the effect of deodorant and antiperspirant use and the presence of underarm hair on the absorption of testosterone. Each participant in this study will receive 6 single doses of 30 milligrams (mg) testosterone applied as a solution to each underarm. There is a minimum one da...

What is the current status of trial NCT01725451?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-11. Estimated completion is 2013-01.

What interventions are being tested in trial NCT01725451?

The interventions under investigation include: Testosterone (DRUG), Deodorant Spray (OTHER), Deodorant and Antiperspirant Combination Spray (OTHER), Deodorant and Antiperspirant Combination Stick (OTHER).

Who is sponsoring clinical trial NCT01725451?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01725451's enrollment target sits among peer trials

30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01725451, the US trial registry maintained by the National Library of Medicine. NCT01725451 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.